

**Stichting European Uro-Oncology Group (EUOG)**  
**Zernikedreef 8**  
**2333 CL LEIDEN**

**ANNUAL REPORT 2019**

<b>TABLE OF CONTENTS</b>	<b>Blz.</b>
<b><u>Management board's report</u></b>	<b>3</b>
<b><u>Financial Statements 2019</u></b>	
Balance sheet as at 31 December 2019	6
Profit & loss account for the year 2019	8
Notes to the financial statements	9
Notes to various items on the balance sheet	10
Off balance sheet commitments	10
(proposition to) appropriation of the positive / negative balance	10
Events subsequent to the balance sheet date	10

## Report from the Board EUOG 2019

### General

The Board has been gathered 4 times in 2019: on location or by telephone/videoconferences, on February 5, April 26, August 2 and October 21. In May 2019, Dr. Loidl from Austria has joined the Board bringing the total size of the Board of Directors to 5 members. One of the members has announced to withdraw from the Board in 2020.

There have been no changes in number of employees at the secretariat/trial office. The office is run by 2 employees.

The EUOG has organized a meeting for members, urologists, oncologists and pathologists, during the EAU congress in Barcelona. The status of ongoing studies was discussed, new studies discussed. A new proposal will be further developed by a dedicated group of members.

During the strategy meeting on August 2, the Board discussed expansion and diversifying the portfolio of the EUOG. Collaboration with patient advocacy groups was prioritized and pursued. The expert opinion of external advisors with extensive experience in the field of oncology was sought with regard to adapted upscaling of EUOG growth strategies; in November 2019, extensive consultation was done.

Information about EUOG's mission in 2020 and beyond and strategy and -in accordance with requirements for the 'ANBI status (non-profit, charity foundation)- the annual report can be found on the website [www.euog.org](http://www.euog.org).

The financial statements have been prepared by Bunnig & Partners Accountants in Leiden in cooperation with the Foundation.

### Research

There are 3 EUOG studies in progress, a 4<sup>th</sup> study for 'intravenous liposomal dexamethasone in patients with metastatic prostate cancer', co-developed by EUOG has recently been finalized. Two new ones are under development.

Two studies investigate the clinical utility of WB MRI and PET CT scan in patients with hormone-sensitive metastatic prostate cancer ("HORNA study") or chemotherapy-naïve metastatic castration-resistant prostate cancer ("CHENA study") undergoing enzalutamide treatment. The target number of patients has been reached for HORNA and the study closed for accrual. The CHENA study is ongoing.

The URANUS study explores feasibility, efficacy and outcome in patients with upper urinary tract urothelial cell carcinoma (UTUC) scheduled to undergo surgery, who are randomized to neoadjuvant or adjuvant chemotherapy, or undergo surgery alone when unfit for chemotherapy. The trial is in progress. Expansion of centers for this rare cancer type is ongoing and has resulted in a considerable increase in workload for the EUOG trial office.

An Upper Tract Urothelial Carcinoma (UTUC) International Collaborative Database Consortium (UICD) investigating prediction models and across countries outcome differences has been launched, dedicated members convene regularly. Further expansion to other continents for the global consortium is pursued.

### Financial report

The revenues in 2019 were partially coming from grants, among others from Astellas. Furthermore, in 2019 the liquid assets has increased considerably. An associated non-profit organization I VZW in Belgium with similar research aims and objectives, ceased to exist; by valid decision under the liquidation procedure of this NGO, the available securities portfolio (€ 1.777.830) were transferred to the EUOG on 4 November 2019, while maintaining the existing banking relationship of the former IVZW in Belgium. The

date of the Transfer Agreement regarding the assets of the EUOG IVZW is December 5, 2019, the actual transfer has been formalized on December 16<sup>th</sup>, 2019 during a special general meeting of the I VZW.

The expenses of the EUOG Foundation were for daily operational costs, as salaries, insurances, administrative, juridical and accountant expenses. Furthermore, the foundation has paid substantial amounts for reimbursement to participating hospitals in studies to compensate expenses as agreed upon.

The balance on the bank account was on December 31, 2019 exactly € 2.002.398.

### **Conclusion**

The Foundation has made progress in ongoing studies and participation by more members from different centers and countries is being realized. Its portfolio has been enlarged and underscores broad interest and support to participate in urological cancer studies. The Foundation contributes to cancer research through Europe and beyond, with the aim to find new and better solutions for cancer patients. To make this possible and to continue these activities, the Foundation is striving to obtain grants, donations and gifts.

Leiden, June 23, 2020

signed

Chairman, S. Osanto

(on behalf of the entire board)

Treasurer, I.J. de Jong

(agreed during the board meeting)

Board member, L.G. Beckers

(agreed during the board meeting)

Board member, W. Loidl

(agreed during the board meeting)

Board member, H. van Poppel

(agreed during the board meeting)

**FINANCIAL STATEMENTS 2019**  
**OF**  
**STICHTING EUROPEAN URO-ONCOLOGY GROUP**



**BALANCE as at December 31 2019**

<b>ASSETS</b>	<b>31-12-2019</b> €	<b>31-12-2018</b> €
<b>Fixed assets</b>		
Tangible fixed assts:		
Inventory	0	0
Means of transport	<u>0</u>	<u>0</u>
	0	0
<b>Current assets</b>		
Debtors	0	0
Taxes and social securities	0	0
Other receivables (1)	30.000	0
Cash and cash equivalents (2)	<u>2.002.398</u>	<u>242.825</u>
	2.032.398	242.825
<b>Total assets</b>	<u>2.032.398</u>	<u>242.825</u>

**of Stichting European Uro-Oncology Group** **after determination of the result**

<b>EQUITY AND LIABILITIES</b>	<b>31-12-2019</b>	<b>31-12-2018</b>
	<b>€</b>	<b>€</b>
<b>Foundation capital</b>		
Designated reserve (3)	1.969.252	147.446
<b>Current liabilities</b>		
Taxes and social securities	0	0
Creditors (4)	2.183	0
Other liabilities (5)	<u>60.963</u>	<u>95.379</u>
	63.146	95.379
<b>Total equity and liabilities</b>	<u>2.032.398</u>	<u>242.825</u>

**PROFIT & LOSS ACCOUNT FOR THE YEAR 2019**

		<b>Realization 2019 €</b>	<b>Realization 2018 €</b>
<b>PROFITS</b>			
Grants/subsidy	(6)	88.500	146.250
Other profits		1.982.060	1.632
<b>Sum of profits</b>		<u>2.070.560</u>	<u>147.882</u>
<b>EXPENSES</b>			
Research costs	(7)	141.357	155.975
Wages and salaries	(8)	93.206	78.954
Other expenses	(9)	14.191	10.704
<b>Sum of expenses</b>		<u>248.754</u>	<u>245.633</u>
<b>Result</b>		<u>1.821.806</u>	<u>-97.751</u>



## **NOTES TO THE FINANCIAL STATEMENTS**

Statutory name: Stichting European Uro-Oncology Group

Registered address: Leiden

### **Principles of valuation**

#### **General**

The financial statements have been prepared in accordance with the provisions of the Annual Reporting Guideline "C1 Small Organizations-Without-Profit"

The financial statements of the company are presented in euros, which is the company's functional currency. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

The income and expenses are accounted for in the period to which they relate. Obligations and possible expenses that originate before the end of the reporting year are taken into account if and insofar as they have become known before the preparation of the financial statements. Depreciation of fixed assets is based on the acquisition value. Depreciation takes place according to the straight-line method based on the estimated economic life.

### **PRINCIPLES OF VALUATION OF ASSETS AND LIABILITIES**

#### **Trade and other receivables**

The receivables are initially valued at its fair value, and subsequently valued at amortised cost, which is similar to the face value, after deduction of any provisions if necessary.

#### **Cash and cash equivalents**

Cash and cash equivalents are valued at nominal value.

#### **Liabilities**

Current liabilities are initially valued at its fair value, and subsequently valued at amortised cost, which is similar to the face value. Accruals are valued at its face value.

### **PRINCIPLES FOR THE DETERMINATION OF THE RESULT**

#### **General**

The result is defined as the difference between the profits on one hand and on the other hand the costs and expenses for that year, valued at historical costs. They are determined in accordance with the aforementioned valuation principles. Profits are recognized in the year in which the goods were delivered or the services rendered. Losses originating in the financial year are taken into account as soon as they are foreseeable.

#### **Grants/subsidy**

Grants are recognized as income in the statement of profits & loss in the year in which the subsidized costs were incurred or revenues were lost, or when a subsidized operating deficit occurred. The subsidy recognized when it is probable that it will be received.

## NOTES TO VARIOUS ITEMS ON THE BALANCE SHEET

### **EQUITY AND LIABILITIES**

#### **Foundation capital**

#### **3. Foundation capital**

#### **Designated reserve**

The mutations are as follows:

	<b>2019</b>	<b>2018</b>
	<b>€</b>	<b>€</b>
Balance as at 1 January	147.446	245.197
Mutation	1.821.806	-97.751
Balance as at 31 December	<u>1.969.252</u>	<u>147.446</u>

The designated reserve of Stichting EUOG originated from the grants received from various parties and is exclusively intended for the prescribed research.

### **OFF-BALANCE SHEET COMMITMENTS**

### **OTHER EXPLANATORY NOTES**

#### **Proposition to appropriation of the positive / negative balance**

The board proposes to add the result to the freely available capital of the foundation by means of an addition to the foundation capital.

#### **Events with financial consequences subsequent to the balance sheet date**

There have been no events affecting this report between the balance sheet date and the time of drawing up the balance sheet.